Click here to view online. Add this email to your safelist.
Phase III ZONDA trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients
22 May 2017
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control. Detailed results of the ZONDA study were published today online in the New England Journal of Medicine.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
